Considering that, during the progression of AD, inflammatory factors perform a significant role in neuronal and synaptic loss, and also in behavioral impairments, it is suggested in this study that the neuroprotective effects of MC therapy may stem from its TLR4-MyD88-NFκB-dependent anti-inflammatory actions. This evidence concerns the gene NFKB1 and Alzheimer disease.